​

Funding Round

Series D - OncoResponse

Series D - OncoResponse

Investment Firm

Overview

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

Announced Date

May 18, 2023

Funding Type

Series D

Highlights

Location

United States, North America

Social

Investor Lead

RiverVest

RiverVest

RiverVest is a early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

6

Investor Name
Participant InvestorTakeda Ventures
Participant InvestorBering Capital
Participant InvestorRiverVest
Participant InvestorARCH Venture Partners
Participant InvestorCanaan Partners

Round Details and Background

OncoResponse raised $14000000 on 2023-05-18 in Series D

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

Company Funding History

7

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 18, 2023
Series D - OncoResponse
7-14.0M
Mar 09, 2017
Series A - OncoResponse
-3.0M
Oct 10, 2016
Series A - OncoResponse
2-7.0M
May 07, 2016
Series A - OncoResponse
6-12.5M

Recent Activity

There is no recent news or activity for this profile.